Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 May;38(5):1118–1122. doi: 10.1128/aac.38.5.1118

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.

K Fujii 1, A Tsuji 1, S Miyazaki 1, K Yamaguchi 1, S Goto 1
PMCID: PMC188160  PMID: 8067748

Abstract

The in vitro and in vivo antibacterial activities of the new rifamycin derivatives KRM-1648 and KRM-1657 were compared with those of rifampin. Rifabutin, ciprofloxacin, and clarithromycin were also tested for reference. The respective MICs of KRM-1648 and KRM-1657 for 90% of the strains tested (MIC90S) were 0.016 and 0.0078 microgram/ml, respectively, for methicillin-susceptible Staphylococcus aureus, 0.016 and 0.0039 microgram/ml, respectively, for methicillin-resistant S. aureus, and 0.0625 and 0.016 microgram/ml, respectively, for methicillin- and quinolone-resistant S. aureus. These MIC90S of KRM-1657 were equal to or 2- to 64-fold lower than those of rifampin. KRM-1648 and KRM-1657 with MIC90S of between 0.002 and 0.078 microgram/ml were 2- to 128-fold more active than rifampin against Staphylococcus epidermidis and Streptococcus species, including Streptococcus pneumoniae and Streptococcus pyogenes. The MIC90S of KRM-1657 for Haemophilus influenzae and Neisseria gonorrhoeae were 0.25 and 0.1 microgram/ml, respectively; KRM-1657 was almost as active as rifampin and was 8- to 16-fold more active than KRM-1648 against these strains. The frequency of occurrence of spontaneous mutations to resistance to KRM-1648 and KRM-1657 was equal to that to rifampin. Against systemic infection with S. aureus in mice, the efficacies of KRM-1648 and KRM-1657 were comparable to that of rifampin.

Full text

PDF
1118

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Emori M., Saito H., Sato K., Tomioka H., Setogawa T., Hidaka T. Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother. 1993 Apr;37(4):722–728. doi: 10.1128/aac.37.4.722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eng R. H., Smith S. M., Buccini F. J., Cherubin C. E. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother. 1985 Feb;15(2):201–207. doi: 10.1093/jac/15.2.201. [DOI] [PubMed] [Google Scholar]
  3. Kuze F., Yamamoto T., Amitani R., Suzuki K. [In vivo activities of new rifamycin derivatives against mycobacteria]. Kekkaku. 1991 Jan;66(1):7–12. [PubMed] [Google Scholar]
  4. Saito H., Tomioka H., Sato K., Emori M., Yamane T., Yamashita K., Hosoe K., Hidaka T. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991 Mar;35(3):542–547. doi: 10.1128/aac.35.3.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Sande M. A., Scheld W. M. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med. 1980 Mar;92(3):390–395. doi: 10.7326/0003-4819-92-3-390. [DOI] [PubMed] [Google Scholar]
  6. Tomioka H., Saito H., Fujii K., Sato K., Hidaka T. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrob Agents Chemother. 1993 Jan;37(1):67–70. doi: 10.1128/aac.37.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Tomioka H., Saito H., Sato K., Yamane T., Yamashita K., Hosoe K., Fujii K., Hidaka T. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother. 1992 Feb;36(2):387–393. doi: 10.1128/aac.36.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Yamamoto T., Amitani R., Kuze F., Suzuki K. [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex]. Kekkaku. 1990 Dec;65(12):805–810. [PubMed] [Google Scholar]
  9. Yamane T., Hashizume T., Yamashita K., Konishi E., Hosoe K., Hidaka T., Watanabe K., Kawaharada H., Yamamoto T., Kuze F. Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo) 1993 Jan;41(1):148–155. doi: 10.1248/cpb.41.148. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES